Abstracts tagged "rheumatoid arthritis"

Abstract Number: 0936 • ACR Convergence 2024
Schnurri-3 Inhibition Protects from NF-kB-induced Bone Loss in Inflammatory Arthritis
Priyanka Kushwaha¹, Catherine Manning², Tadatoshi Sato³, Yeon-Suk Yang³, Jae-Hyuck Shim⁴ and Ellen Gravallese⁵, ¹Department of Medicine/Division of Rheumatology, Inflammation and Immunity, Brigham and Women’s Hospital, Boston, MA, ²Brigham and Women's Hospital, Dedham, MA, ³Department of Medicine/Division of Rheumatology, Horae Gene Therapy Center, University of Massachusetts Chan Medical School, Worcester, MA, ⁴University of Massachusetts, Worcester, MA, ⁵Brigham and Women's Hospital, Harvard Medical School, Chestnut Hill, MA
Background/Purpose: In rheumatoid arthritis (RA), production of TNF promotes osteoclast activity and inhibits osteoblasts (OBs) and bone healing. Schnurri-3 (SHN3) is a potent suppressor of…
Abstract Number: 0983 • ACR Convergence 2024
Life Satisfaction in Adults Living with Arthritis – a Cross-Sectional Analysis of the 2022 National Health Interview Survey
Aleksander Lenert¹, Mary E. Charlton¹, Jacob J. Oleson¹, Robyn Domsic² and Polly Ferguson³, ¹University of Iowa, Iowa City, IA, ²Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, ³University of Iowa Carver College of Medicine, Iowa City, IA
Background/Purpose: General well-being, an individual’s subjective assessment of their life overall, may be impacted by arthritis. It is unclear if adults with arthritis have lower…
Abstract Number: 1041 • ACR Convergence 2024
A Theory of Change for Patient-Initiated Follow-Up Care in Rheumatoid Arthritis
Manuel Ester¹, Krista White², Kiran Dhiman², Saania Zafar², Alexandra Charlton³, Glen Hazlewood⁴, Gabrielle L. Zimmermann⁵, Alison Hoens⁶, Sarah L. Manske⁷, Diane Lacaille⁸, Mark G. Perry⁹, Megan R.W. Barber¹⁰, Aurore Fifi-Mah⁴, Niki Panich¹¹, Monika Szpunar¹², Karen Then¹³, Kelly Osinski¹⁴, Shakeel Subdar¹⁵, Hafsah Al-Azem¹⁶, Michelle Jung¹⁶ and Claire Barber⁴, ¹McCaig Institute for Bone and Joint Health, Cumming School of Medicine, University of Calgary; O’Brien Institute for Public Health, Cumming School of Medicine, University of Calgary; Arthritis Research Canada, Calgary, AB, Canada, ²McCaig Institute for Bone and Joint Health, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ³Division of Rheumatology, Cumming School of Medicine, Calgaru, AB, Canada, ⁴University of Calgary, Calgary, AB, Canada, ⁵Alberta SPOR SUPPORT Unit – Learning Health System Team, Department of Medicine, University of Alberta; 6. Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Edmonton, AB, Canada, ⁶Arthritis Research Canada; Department of Physical Therapy, University of British Columbia, Vancouver, BC, Canada, ⁷McCaig Institute for Bone and Joint Health, Cumming School of Medicine, University of Calgary; Department of Radiology, University of Calgary, Calgary, AB, Canada, ⁸Arthritis Research Canada, University of British Columbia, Vancouver, BC, Canada, ⁹Department of Rheumatology, University Hospitals Plymouth; Peninsula Medical School, Plymouth, England, United Kingdom, ¹⁰Arthritis Research Canada; Division of Rheumatology, Cumming School of Medicine, Calgary, AB, Canada, ¹¹Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ¹²Arthritis Research Canada, Toronto, ON, Canada, ¹³Faculty of Nursing, University of Calgary, Calgary, AB, Canada, ¹⁴Alberta Health Services, Edmonton, AB, Canada, ¹⁵Temerty School of Medicine, University of Toronto, Toronto, ON, Canada, ¹⁶Division of Rheumatology, Cumming School of Medicine, Calgary, AB, Canada
Background/Purpose: Timely, high-quality care is critical to effective rheumatoid arthritis (RA) management. Due to the resource-intensive nature of routine lifelong follow-ups and rheumatologist shortages, RA…
Abstract Number: 1248 • ACR Convergence 2024
Most Prevalent Self-Reported Comorbidities Among Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Axial Spondyloarthritis
Shilpa Venkatachalam¹, Jeffrey Curtis², Anne Sydor³, Erik Stone⁴, Angela Degrassi³, Esteban Rivera⁵, Laura Stradford⁶ and Kelly Gavigan³, ¹Global Healthy Living Foundation, New York, NY, ²University of Alabama at Birmingham, Hoover, AL, ³Global Healthy Living Foundation, Upper Nyack, NY, ⁴Global Healthy Living Foundation, Upper Nyack, ⁵Global Healthy Living Foundation, Long Island City, NY, ⁶Global Healthy Living Foundation, Nyack, NY
Background/Purpose: Many people with inflammatory arthritis live with other serious chronic conditions that may affect their quality of life and ability to effectively manage their…
Abstract Number: 1337 • ACR Convergence 2024
Gender and Ethnic Differences (or Lack Thereof) in Perceived Disease Burden in RA
Ali Malik¹, Dennis Ang¹, Adam Hall¹, John Herion¹ and Rupak Thapa², ¹Wake Forest University, Winston Salem, NC, ²Assistant Professor, Winston Salem, NC
Background/Purpose: Gender and ethnic disparities in health care are well reported in the general medical literature. Differences in symptom reporting or perceived health status can…
Abstract Number: 1353 • ACR Convergence 2024
Association Between Frailty and Incident Cancer in Newly Diagnosed Rheumatoid Arthritis
Bhavik Bansal¹, Laura Gold², Katherine Wysham³, James Andrews⁴, Alexa Meara⁵, Carolyn Presley⁶, Elad Sharon⁷, Jiha Lee⁸, Jennifer Barton⁹, Una Makris¹⁰ and Namrata Singh¹¹, ¹All India Institute of Medical Sciences, New Delhi, Delhi, India, ²University of Washington, Seattle, ³VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵The Ohio State University Wexner Medical Center, COLUMBUS, OH, ⁶The Ohio State Medical Center, Columbus, OH, ⁷Dana Farber Cancer Institute, Boston, MA, ⁸University of Michigan, Ann Arbor, MI, ⁹VA Portland Health Care System/OHSU, Portland, OR, ¹⁰UT Southwestern Medical Center and Dallas VA, Dallas, TX, ¹¹University of Washington, Bellevue, WA
Background/Purpose: Rheumatoid Arthritis (RA) is associated with an increased risk of cancer, but the underlying risk factors remain poorly understood. Frailty is linked to an…
Abstract Number: 1369 • ACR Convergence 2024
Persistence, Effectiveness and Treatment Patterns of Upadacitinib in over 2600 Australian Rheumatoid Arthritis Patients: A Retrospective Analysis from the OPAL Dataset
Peter Youssef¹, Sabina Ciciriello², Talib Tahir³, Tegan Smith⁴, Catherine O'Sullivan⁴, Joanna Leadbetter⁵, Belinda Butcher⁵, Nicole Walsh⁶, Miriam Calao⁶ and Geoffrey Littlejohn⁷, ¹Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia, ²The University of Melbourne, Melbourne, Victoria, Australia, ³Coburg Rheumatology Service, Coburg, Victoria, Australia, ⁴OPAL Rheumatology Ltd, Geelong, Victoria, Australia, ⁵WriteSource Medical Pty Ltd, Lane Cove, New South Wales, Australia, ⁶AbbVie Pty Ltd, Mascot, New South Wales, Australia, ⁷Monash University, Clayton, Victoria, Australia
Background/Purpose: To describe the real-world treatment patterns, response and persistence in rheumatoid arthritis (RA) patients (pts) treated with upadacitinib (UPA).Methods: This retrospective, non-interventional, multicenter cohort…
Abstract Number: 1386 • ACR Convergence 2024
Olokizumab in Real Clinical Practice: Efficacy and Safety
Sofia Kuzkina¹, Alena Zagrebneva², Galym Togizbayev³, Elvira Aitova⁴, Nataliya Belozerova⁵, Irina Patrikeeva⁶, Ruzana Samigullina⁷, Mikhail Sostak⁷, Evgeniya Jakovleva⁸, Anton Chudinov⁹, Antonina Dolgorukova¹⁰, Evgeniy Alekseev¹¹ and EVGENY NASONOV¹², ¹R-Pharm, Moscow, Russia, ²Clinical hospital #52, Moscow, Russia, ³Kazakh National Medical University named after Asfendiyarov S, Almaty, Kazakhstan, ⁴Clinic of Bashkir State Medical University, Ufa, Russia, ⁵SBIHC «Region clinic hospital Nr 2»; SBEA HE «Kuban state medical university»,, Krasnodar, Russia, ⁶GBUZ Tyumen Regional Clinical Hospital N 1, Tyumen, Russia, ⁷North-Western State Medical University named after I.I. Mechnikov, Saint-Petersburg, Russia, ⁸Scientific Research Institute - Ochapovsky Regional Clinical Hospital no. 1, Krasnodar, Russia, ⁹Clinical Rheumatology Hospital No.25; North-West State Medical University named after I.I.Mechnikov, Saint-Petersburg, Russia, ¹⁰R-Pharm, JSC, Moscow, Russia, ¹¹R-Pharm, JSC, Saint-Petersburg, Russia, ¹²V.A. Nasonova Research Institute of Rheumatology; I.M. Sechenov First Moscow State Medical University, Moscow, Russia
Background/Purpose: Olokizumab (OKZ) is a direct inhibitor of interleukin 6, which has shown significant symptom reduction in RA patients, however there is a lack of…
Abstract Number: 1403 • ACR Convergence 2024
Development, Validation and Clinical Use of Health-Related Behaviour Health Fitness Questionnaire (HR-BHF) in Indian (Asian) Subjects Attending a Community Rheumatology Center
MANJIT SALUJA¹ and ARVIND CHOPRA², ¹CENTER FOR RHEUMATIC DISESAES, Pune, Maharashtra, India, ²CENTER FOR RHEUMATIC DISEASES, Pune, Maharashtra, India
Background/Purpose: Our patients often express concerns related to ‘wellbeing’ that are not routinely attended during standard care (including QOL). Alternatively, these concerns are important components…
Abstract Number: 1681 • ACR Convergence 2024
Safe Switching from Originator Tocilizumab to MSB11456 Tocilizumab Biosimilar in Subjects with Moderate-to-Severe Rheumatoid Arthritis: Efficacy, Safety and Immunogenicity Data Following Treatment Transition in a Pivotal, Randomized, Double-blind, Phase III Study
Anna Zubrzycka-Sienkiewicz¹, Kamilla Klama², Martin Ullmann³, Corinne Petit-Frere³, Andras Illes³, Olga Menang³, Joëlle Monnet³ and Peter Baker³, ¹Reumatika - Centrum Reumatologil", NZOZ, Warszawa, Poland, ²Solumed Centrum Medyczne, Poznań, Poland, ³Fresenius Kabi SwissBioSim GmbH, Eysins, Switzerland
Background/Purpose: A therapy transition from the originator to a biosimilar offers significant advantages for patients by lowering medication costs and improving accessibility to treatments. MSB11456…
Abstract Number: 1845 • ACR Convergence 2024
Treg Expansion and IL-6 Induced STAT3 Phosphorylation in CD4+ T Cells Is a Biomarker of Disease Flare in Rheumatoid Arthritis
Amy Anderson¹, Luke Jones², Fiona Rayner³, Jessica Swift¹, Daniel Maunder¹, Henrique de Paula Lemos¹, David Swan⁴, Abbie Degnan¹, Imogen Wilson¹, Julie Diboll¹, Gary Reynolds¹, Jasmine Sim¹, Andrew Melville⁵, Stefan Siebert⁵, Iain McInnes⁶, Carl Goodyear⁵, Catharien Hilkens¹, Karim Raza⁷, Christopher Buckley⁸, Kenneth Baker¹, Arthur Pratt³, Andrew Filer⁷ and John Isaacs¹, ¹Translational and Clinical Research Institute, NIHR Newcastle Biomedical Research Centre, Newcastle University and The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom, ²Rheumatology Research Group, Institute for Inflammation and Ageing, NIHR Birmingham Biomedical Research Center and Clinical Research Facility, Birmingham, United Kingdom, ³Translational and Clinical Research Institute, NIHR Newcastle Biomedical Research Centre, Newcastle University and The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, England, United Kingdom, ⁴Translational and Clinical Research Institute, NIHR Newcastle Biomedical Research Centre, Newcastle University and The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, ⁵School of Infection and Immunity, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom, ⁶University of Glasgow, College of Medical Veterinary and Life Sciences, Glasgow, United Kingdom, ⁷Rheumatology Research Group, Institute for Inflammation and Ageing, NIHR Birmingham Biomedical Research Center and Clinical Research Facility, University of Birmingham, Birmingham, United Kingdom, ⁸Kennedy Institute of Rheumatology, University of Oxford, Oxford, United Kingdom
Background/Purpose: Understanding the mechanisms that drive disease flares in patients with rheumatoid arthritis (RA) may aid in the development of biomarkers to facilitate targeted treatment…
Abstract Number: 1903 • ACR Convergence 2024
Impact of Multimorbidity on Targeted Synthetic and Biologic Disease-modifying Antirheumatic Drug (ts/bDMARD) Effectiveness in Patients with Rheumatoid Arthritis: A Two Year Follow-up Study from Mexican Adverse Events Registry BIOADAMEX
Vijaya Rivera Teran¹, David Vega Morales², Iris Jazmín Colunga Pedraza³, Sandra Sicsik Ayala⁴, Angel Alejandro Castillo Ortiz⁵, Miguel Angel Saavedra Salinas⁶, Dafhne Miranda Hernández⁷, Fedra Irazoque Palazuelos⁸, Julio César Casasola Vargas⁹, Omar Eloy Muñoz Monroy¹⁰, Sandra Carrillo Vazquez⁸, javier Merayo Chalico¹¹, Guillermo Guaracha Basañez¹², Estefania Torres Valdez¹³, Luis Valdés Corona¹⁴, Angélica Peña Ayala¹⁵, Sergio Durán Barragán¹⁶, Azucena Ramos Sánchez², Aleni Paz Viscarra¹⁴, Erick Adrián Zamora Tehozol¹⁷, Daniel Xibillé Friedman¹⁸ and Jiram Torres Ruiz¹⁹, ¹Colegio Mexicano de Reumatología, Mexico City, Mexico, ²Instituto Mexicano del Seguro Social, Monterrey, Mexico, ³Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ⁴Instituto Mexicano del Seguro Social, Torreón, Mexico, ⁵Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado, Merida, Mexico, ⁶División de Investigación en Salud, Hospital de Especialidades Dr. Antonio Fraga Mouret, CMN La Raza, CDMX, Mexico, ⁷Instituto Mexicano del Seguro Social, Mexico City, Mexico, ⁸Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado, Mexico City, Mexico, ⁹Hospital General de México, “Dr.Eduardo Liceaga”, MEXICO CITY, Mexico, ¹⁰Hospital Central Militar, Mexico City, Mexico, ¹¹Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, CDMX, Mexico, ¹²Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirón", Mexico City, Mexico, ¹³Instituto Mexicano del Seguro Social, Querétaro, Mexico, ¹⁴Práctica Privada, Mexico City, Mexico, ¹⁵Instituto Nacional de Rehabilitación "Luis Guillermo Ibarra Ibarra", Ciudad de Mexico, Distrito Federal, Mexico, ¹⁶Clínica de Investigación en Reumatología, Guadalajara, Mexico, ¹⁷Práctica Privada, Merida, Mexico, ¹⁸Práctica Privada, Cuernavaca, Mexico, ¹⁹INCMNSZ, Mexico, Federal District, Mexico
Background/Purpose: To evaluate the impact of multimorbidity on the effectiveness of targeted synthetic and biologic disease-modifying antirheumatic drug (ts/bDMARD), in patients with rheumatoid arthritis in a two-year follow-up.Methods:…
Abstract Number: 2118 • ACR Convergence 2024
Cytotoxic T Lymphocyte Antigen-4 Improves Osteoporosis in Patient with Rheumatoid Arthritis
Yen-An Chang¹ and Ming‑Han Chen², ¹Division of Allergy, Immunology, Rheumatology/Department of Medicint/Taipei Veterans General Hospital, Taipei City, Taiwan (Republic of China), ²Division of Allergy, Immunology & Rheumatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, Taipei, Taiwan
Background/Purpose: Rheumatoid arthritis (RA) is recognized as a risk factor for osteoporosis. Cytotoxic T Lymphocyte Antigen-4 (CTLA-4) acts as an inhibitory regulator post-T cell activation,…
Abstract Number: 2216 • ACR Convergence 2024
Additive Impact of Rheumatoid Arthritis and HBcAb+ on All-cause and Cardiovascular Mortality
Leiyi Yang¹, Bo Chen², Qibing Xie³ and Geng Yin⁴, ¹Sichuan University, Cheng Du Shi, Sichuan, China (People's Republic), ²Chenbo, Chendu, Sichuan, China, ³Department of Rheumatology and Immunology, Chengdu, Sichuan, China, ⁴Department of Rheumatology and Immunology, chengdu, China (People's Republic)
Background/Purpose: Rheumatoid arthritis (RA) and hepatitis B both have a high incidence and significant health impacts, possibly sharing a pathogenic connection. Notably, a considerable proportion of…
Abstract Number: 2233 • ACR Convergence 2024
Maximizing Diagnostic Sensitivity: Combined Anti-RA33, Anti-CarP, and Anti-PAD4 Autoantibodies in Seronegative Rheumatoid Arthritis
Andrew Concoff¹, Touba Warsi², Sepehr Taghavi², Sudha Kumar², Abigail Patalinghug², Christine Schleif², Brittany Partain³, Joseph Ahearn⁴, Susan Manzi⁵, Michael Mahler⁶, Veena Joy⁷ and Tyler O'Malley⁸, ¹Exagen, Inc., Los Angeles, CA, ²Exagen, Carlsbad, CA, ³Exagen, Boston, MA, ⁴Allegheny Health Network, Wexford, PA, ⁵Allegheny Health Network, Pittsburgh, PA, ⁶Werfen, San Diego, CA, ⁷ThermoFisher, Philadelphia, PA, ⁸Exagen, Vista, CA
Background/Purpose: Studies have found autoantibodies (Ab) directed against heterogeneous nuclear ribonucleoprotein A2/B1 (anti-RA33), peptidyl arginine deiminase 4 (anti-PAD4) and carbamylated proteins (anti-CarP) each have diagnostic…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].